Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study.
Oscar FernándezGuillermo IzquierdoEduardo AgueraCristina RamoMiguel HernandezDiego SilvaRob WalkerHelmut ButzkuevenChenyu WangMichael Harry Barnettnull nullPublished in: Multiple sclerosis journal - experimental, translational and clinical (2020)
Fingolimod appeared equally effective as first- or second-line therapy in relapsing MS. There was a trend for better outcomes with fingolimod in treatment-naïve patients than in those previously treated with >1 iDMT.
Keyphrases
- multiple sclerosis
- end stage renal disease
- open label
- newly diagnosed
- ejection fraction
- chronic kidney disease
- clinical trial
- mass spectrometry
- peritoneal dialysis
- stem cells
- randomized controlled trial
- type diabetes
- metabolic syndrome
- adipose tissue
- ms ms
- study protocol
- systemic lupus erythematosus
- patient reported outcomes
- phase ii
- replacement therapy
- combination therapy
- mesenchymal stem cells
- skeletal muscle
- phase ii study
- cell therapy
- smoking cessation